Covagen Company

Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architecturesto maximize efficacy. Their goal is to access novel biology for each product candidate. Covagen’s lead FynomAb COVA322 is being developed for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis.
Technology: Data-driven Technologies
Industry: Geroscience
Headquarters: Zurich
Founded Date: 2007
Employees Number: 11-50
Funding Status: M&A
Total Funding: $10.6M
Estimated Revenue: $10M to $50M
Last Funding Type: Venture - Series Unknown

Visit Website
Register and Claim Ownership